Regulus Acquires IP Related to miR-21 Modulation | GenomeWeb

Regulus Therapeutics this week announced that it has acquired from the University of Wuerzburg the exclusive rights to intellectual property covering methods for modulating microRNA-21.

According to the company, the miRNA has been shown to be dysregulated in mouse models of cardiac disease and fibrosis, and "antagonizing miR-21 with therapeutic oligonucleotides … inhibits fibrosis and attenuates cardiac function in such models."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.